Direct thrombin inhibitors (part 1 of 2).
Arora
Umesh K
UK
Department of Medicine, Cardiology, University of Texas HSC at San Antonio, San Antonio, Texas 78229, USA. umeen2111@aol.com
Dhir
Meeney
M
D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D000991:Antithrombins / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; D013917:Thrombin